For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ Calcitonin salmon
Illustration for Calcitonin salmon

THE PEPSRADAR ENCYCLOPEDIA

Calcitonin salmon

Calcium regulation and bone conditions

Prescription medicines · Sources checked 2026-10-04

Read the studies ↓Explore the molecule ↗

Calcitonin salmon · KEY FACTS

Content updated · how dates work

Saved peptides

What is Calcitonin salmon?

Salmon calcitonin is a hormone medicine that reduces bone breakdown. Injectable and nasal preparations have distinct clinical histories and instructions.

Biological role or research focus

Calcium regulation and bone conditions.

The exact formulation and indication matter; a peptide category does not describe a universal bone treatment.

Role reference: MedlinePlus · Calcitonin salmon ↗

Names you may encounter

calcitonin

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
Calcium-regulating hormone
Main research area
Bone resorption and blood calcium
Evidence featured
Human randomized trial
Source check
October 4, 2026

Source: MedlinePlus · Calcitonin salmon ↗

Quick answers

Is Calcitonin salmon FDA approved?
Yes. Miacalcin injection (NDA 017808) for Paget's disease of bone, hypercalcemia and postmenopausal osteoporosis. Source ↗
Is Calcitonin salmon safe?
Older approved hormone drug for Paget's disease, high calcium and osteoporosis; key concerns are serious allergic reactions, low calcium and a possible small increase in cancer risk. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
Is Calcitonin salmon banned in sport?
It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

1 Human research
StudyTypePopulation / model
PROOF (2000)Human randomized trial1,255 postmenopausal women with established osteoporosis.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Human randomized trial · 2000

PROOF

A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.

Population / model
1,255 postmenopausal women with established osteoporosis.
Study design
Five-year nasal-spray study; all groups also received calcium and vitamin D.
Main finding
The prespecified middle-dose group had fewer new vertebral fractures than placebo: 51/287 versus 70/270; relative risk 0.67. The other dose groups did not significantly differ from placebo.
Limits & context
Only 511 participants completed five years. Attrition and the inconsistent dose response matter. Nasal-spray findings should not be transferred automatically to injectable products or every fracture type.

Source: A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

32 registered studies name Calcitonin salmon as an intervention among the 100 most recently updated of 155 search results; 6 are recruiting or under way, 2 have not started recruiting yet, 15 completed and 9 ended early, were withdrawn or have another status. Checked November 14, 2026 on ClinicalTrials.gov.

StudyStatusPhaseStartPeople
Psychological Support for Chronic Migraine Patients Treated With Anti-CGRP (Anti-Calcitonin Gene-Related Peptide ) Monoclonal Antibodies
NCT07877493 · Central Hospital, Nancy, France
Not yet recruiting2026-1030
Beijing Osteoporosis With Neurological Disorders in Epigenetic Changes Study
NCT03401619 · Peking University Third Hospital
Active, not recruiting2017-09-212000
Subcutaneous Calcitonin in Acute Herpes Zoster
NCT07655804 · Tanta University
RecruitingPhase 32026-07-01168
Calcitonin Gene-related Peptide Antibody in Acute Mountain Sickness
NCT07653516 · Insel Gruppe AG, University Hospital Bern
Not yet recruitingPhase 42027-06-0130
Paravertebral Calcitonin in Thoracotomy
NCT06330168 · Tanta University
CompletedNot applicable2024-03-2892
Calcitonin Therapy on Incidence and Severity of Neuropathic Pain After Spinal Cord Injury
NCT05805683 · Tanta University
RecruitingNot applicable2023-05-01126
Plasma Calcitonin Gene-Related Peptide (CGRP) Levels in Patients With Head and Neck Malignancies Undergoing Radiotherapy
NCT07029373 · West China Hospital
Completed2025-07-0423
Induction of Migraine Attacks With Aura Using Calcitonin Gene-Related Peptide
NCT07021859 · Danish Headache Center
RecruitingNot applicable2025-06-2721

A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 32 listed studies.

Further reading · 4 additional publication links

Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.

Calcitonin. ↗
· 2006 · Review

Calcitonin Stewardship Strategies. ↗
Journal of pharmacy practice · 2019 Oct · Journal Article, Review

Treatment of postmenopausal osteoporosis. ↗
Pharmacotherapy · 2005 Apr · Journal Article, Review

Primary Osteoporosis Induced by Androgen and Estrogen Deficiency: The Molecular and Cellular Perspective on Pathophysiological Mechanisms and Treatments. ↗
International journal of molecular sciences · 2024 Nov 12 · Journal Article, Review
Read available full text ↗

Repeat this PubMed search ↗
Search additional PubMed records ↗

Risks & interactions

Older approved hormone drug for Paget's disease, high calcium and osteoporosis; key concerns are serious allergic reactions, low calcium and a possible small increase in cancer risk.

Human safety data: FDA label

Safety comes from FDA-approved labeling (Miacalcin) based on open-label trials lasting several months to two years and a pooled analysis of 21 controlled trials of other calcitonin salmon forms. A long-term cancer risk cannot be ruled out.

Take extra care with: Cancer, now or in the past

From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.

Who should not use it

  • People allergic to calcitonin salmon or any ingredient (reactions have included fatal anaphylaxis)

Interactions

  • Lithium: calcitonin can lower lithium levels by increasing its removal in urine

Serious risks

  • Serious allergic reactions, including fatal anaphylaxis, bronchospasm and throat swelling
  • Low blood calcium with muscle cramps, twitching or seizures
  • Possible higher overall cancer risk, seen in a pooled analysis of trials
  • Antibodies that may make the drug stop working
  • Abnormal urine sediment seen in one study of bed-rested volunteers

Common side effects

  • nausea
  • vomiting
  • injection-site inflammation
  • flushing of the face or hands

Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Miacalcin (calcitonin salmon) prescribing information ↗

Key precautions

Allergic reactions, including reactions to salmon calcitonin, require attention. The appropriate benefit-risk assessment depends on the indication, formulation, and current prescribing information.

Source: MedlinePlus · Calcitonin salmon ↗

Regulatory status

U.S. FDA approval
Approved
Miacalcin injection (NDA 017808) for Paget's disease of bone, hypercalcemia and postmenopausal osteoporosis. Nasal spray products (Miacalcin nasal NDA 020313, Fortical) and Calcimar are listed as discontinued. source
FDA compounding (503A bulk list)
Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source
World Anti-Doping Agency (2026)
Not on the WADA Prohibited List
Not named and not within a prohibited class on the 2026 List. source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Clinical uses & product context

The injection reference describes selected osteoporosis, Paget disease, and high-calcium uses. The PROOF study below tested nasal spray in osteoporosis, so its results should be read in that formulation-specific context.

Source: MedlinePlus · Calcitonin salmon ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Why there are no prices here

This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.

Mechanism & research rationale

Calcitonin restrains bone resorption, which differs from the bone-forming approach of teriparatide or abaloparatide. It also influences calcium balance.

Source: MedlinePlus · Calcitonin salmon ↗

Molecular structure

Calcitonin salmon: 2d molecular structure. Salmon calcitonin is shown; human calcitonin has a different sequence.⤢ Enlarge 2D
2D molecular structureSalmon calcitonin is shown; human calcitonin has a different sequence.PubChem · CID 16220016 ↗

Questions worth asking

  • Which indication and formulation does the source describe?
  • Does the video make a broader claim than the source supports?
  • The exact formulation and indication matter; a peptide category does not describe a universal bone treatment.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Frequently asked questions

Why separate nasal and injectable evidence?

Route and formulation change exposure and the clinical use being tested. A nasal-spray fracture study is not an injection study.

Source: MedlinePlus · Calcitonin salmon ↗

Did every PROOF dose reduce fractures?

No. The prespecified middle-dose group differed from placebo; the other groups did not show statistically significant reductions.

Source: A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections

MOLECULAR ATLAS

Calcitonin salmon

Download illustration ↓Source record ↗
Calcitonin salmon 2d molecular structure

Salmon calcitonin is shown; human calcitonin has a different sequence.